Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR. (1st January 2017)

• Record Type: Journal Article
• Authors: Mimoto, Rei; Nihira, Naoe T.; Hirooka, Shinichi; Takeyama, Hiroshi; Yoshida, Kiyotsugu
• Is Part Of: Cancer letters. Volume 384(2017)
• Page Start: 27
• Page End: 38
• Publication Date: 2017-01-01
• Subjects: Breast cancer -- mTOR pathway -- DYRK2 -- Everolimus; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2016.10.015
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Mammalian target of rapamycin (mTOR) inhibitor, everolimus, provides benefit for metastatic hormone receptor positive breast cancer after failure of the endocrine therapy. The present report highlights Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2 (DYRK2) as a predictive marker for everolimus sensitivity. The key node and KEGG pathway analyses revealed that mTORC1 pathway is activated in DYRK2-depleted cells. Everolimus was more effective in DYRK2-depleted cells compared with control cells. In xenograft model, everolimus treatment significantly inhibited tumor growth compared with vehicle or eribulin treatment. In clinical analysis, patients with low DYRK2 expression acquired longer treatment period and had higher clinical benefit rate than those with high DYRK2 expression (171 vs 82 days; P < 0.05 and 50% vs 12.5%, respectively). We further investigated the underlying mechanism by which DYRK2 regulates mTORC1 pathway. The ectopic expression of DYRK2 promoted phosphorylation of Thr631 for the ubiquitination and degradation of mTOR. DYRK2 expression levels may thus predict clinical responses to everolimus. Highlights: mTOR pathway is activated in hormone receptor-positive DYRK2-depleted cells. Everolimus is effective against metastatic breast cancers with low DYRK2 expression. DYRK2 phosphorylates mTOR at Thr631 to promote the degradation of mTOR.